TCGA-AN-A03X-01A-21R-A00Z-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 0
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.640
- ANGIOGENESIS+0.580
- COAGULATION+0.430
- PANCREAS_BETA_CELLS+0.420
- UV_RESPONSE_DN+0.410
- ANDROGEN_RESPONSE+0.350
- APICAL_SURFACE+0.350
- ESTROGEN_RESPONSE_EARLY+0.350
- MYOGENESIS+0.330
- APOPTOSIS+0.320
Top 10 suppressed
- G2M_CHECKPOINT-0.450
- E2F_TARGETS-0.420
- MYC_TARGETS_V1-0.260
- PI3K_AKT_MTOR_SIGNALING-0.240
- MITOTIC_SPINDLE-0.230
- MYC_TARGETS_V2-0.230
- WNT_BETA_CATENIN_SIGNALING-0.180
- DNA_REPAIR-0.160
- ALLOGRAFT_REJECTION-0.140
- SPERMATOGENESIS-0.130
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518353 | — | F | 0.910 |
| 2 | s0099997 | — | — | 0.889 |
| 3 | C3N-04173 | — | cohortA2 | 0.886 |
| 4 | MNG1284 | — | — | 0.882 |
| 5 | SRR15030843 | — | — | 0.881 |
| 6 | TCGA-A2-A0EO-01A-11R-A034-07 | — | A | 0.869 |
| 7 | TCGA-BH-A0HF-01A-11R-A056-07 | — | A | 0.866 |
| 8 | TCGA-22-4605-01A-21R-2125-07 | — | cohortSQ1 | 0.861 |
| 9 | MNG349 | — | — | 0.857 |
| 10 | SRR8613755 | — | F | 0.850 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.640 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.580 | Remibrutinib | — uncovered |
| COAGULATION | 0.430 | Binimetinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.420 | Cobimetinib | — uncovered |
| UV_RESPONSE_DN | 0.410 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.350 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.350 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.350 | Inavolisib | — uncovered |
| MYOGENESIS | 0.330 | Inavolisib | — uncovered |
| APOPTOSIS | 0.320 | Idelalisib | — uncovered |
| HYPOXIA | 0.310 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.310 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.280 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.280 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.280 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.260 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.250 | Inavolisib | — uncovered |
| COMPLEMENT | 0.250 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.250 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.250 | Inavolisib | — uncovered |